<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sevoflurane: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sevoflurane: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sevoflurane: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11863" href="/d/html/11863.html" rel="external">see "Sevoflurane: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F220831"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ultane</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F220864"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        General Anesthetic, Inhalation</li></ul></div>
<div class="block doa drugH1Div" id="F220836"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8fabc082-bd80-45c8-8172-1246c1df2bae">Anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Anesthesia: </b>Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide; the concentration at which amnesia and loss of awareness occur is 0.6% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9447851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9447851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">MAC values for surgical levels of anesthesia:</p>
<p style="text-indent:-2em;margin-left:6em;">25 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Sevoflurane in oxygen: 2.6%</p>
<p style="text-indent:-2em;margin-left:8em;">Sevoflurane in 65% N<sub>2</sub>0/35% oxygen: 1.4%</p>
<p style="text-indent:-2em;margin-left:6em;">40 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Sevoflurane in oxygen: 2.1%</p>
<p style="text-indent:-2em;margin-left:8em;">Sevoflurane in 65% N<sub>2</sub>0/35% oxygen: 1.1%</p>
<p style="text-indent:-2em;margin-left:6em;">60 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Sevoflurane in oxygen: 1.7%</p>
<p style="text-indent:-2em;margin-left:8em;">Sevoflurane in 65% N<sub>2</sub>0/35% oxygen: 0.9%</p>
<p style="text-indent:-2em;margin-left:6em;">80 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Sevoflurane in oxygen: 1.4%</p>
<p style="text-indent:-2em;margin-left:8em;">Sevoflurane in 65% N<sub>2</sub>0/35% oxygen: 0.7%</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991286"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with caution in patients with creatinine &gt;1.5 mg/dL (safety not established).</p></div>
<div class="block doha drugH1Div" id="F50988601"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with caution (safety with severe hepatic impairment has not been studied).</p></div>
<div class="block doe drugH1Div" id="F220837"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. MAC is reduced in the elderly (50% reduction by age 80).</p></div>
<div class="block dop drugH1Div" id="F220850"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8fabc082-bd80-45c8-8172-1246c1df2bae">Anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anesthesia:</b> Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide; the concentration at which amnesia and loss of awareness occur is 0.6% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9447851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9447851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">MAC values for surgical levels of anesthesia:</p>
<p style="text-indent:-2em;margin-left:6em;">0 to 1 month old full-term neonates: Sevoflurane in oxygen: 3.3%</p>
<p style="text-indent:-2em;margin-left:6em;">1 to &lt;6 months: Sevoflurane in oxygen: 3%</p>
<p style="text-indent:-2em;margin-left:6em;">6 months to &lt;1 year:</p>
<p style="text-indent:-2em;margin-left:8em;">Sevoflurane in oxygen: 2.8%</p>
<p style="text-indent:-2em;margin-left:8em;">Sevoflurane in 65% N<sub>2</sub>0/35% oxygen: 2%</p>
<p style="text-indent:-2em;margin-left:6em;">1 to &lt;3 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Sevoflurane in oxygen: 2.8%</p>
<p style="text-indent:-2em;margin-left:8em;">Sevoflurane in 60% N<sub>2</sub>0/40% oxygen: 2%</p>
<p style="text-indent:-2em;margin-left:6em;">3 to 12 years: Sevoflurane in oxygen: 2.5%</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159991"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with caution; has not been studied in adult patients with elevated SCr.</p></div>
<div class="block dohp drugH1Div" id="F51159992"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with caution (safety with severe hepatic impairment has not been studied).</p></div>
<div class="block adr drugH1Div" id="F220810"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adult and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (4% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (25%), vomiting (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (7% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Increased cough (5% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (5%), hypertension (2%), tachycardia (2% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Sialorrhea (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (4%), drowsiness (9%), headache (1%), hypothermia (1%), myoclonus (1%), shivering (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm (2% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Airway obstruction (8%), apnea (2%), breath-holding (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial arrhythmia, atrial fibrillation, bigeminy, cardiac arrhythmia, complete atrioventricular block, depression of ST segment on ECG, inversion T wave on ECG, second degree atrioventricular block, supraventricular extrasystole, syncope, ventricular premature contractions</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis, albuminuria, glycosuria, hyperglycemia, hypophosphatemia, increased lactate dehydrogenase</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dental fluorosis, dysgeusia, hiccups, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Oliguria, urinary retention, urination disorder, urine abnormality</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage, leukocytosis, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion, hypertonia, insomnia, malignant hyperthermia, nervousness, pain</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia, conjunctivitis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, dyspnea, hyperventilation, hypoventilation, hypoxia, increased bronchial secretions, pharyngitis, stridor, wheezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Crying</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, prolonged QT interval on ECG, torsades de pointes</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity (idiosyncratic; Chalasani 2014), jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Delirium, seizure</p></div>
<div class="block coi drugH1Div" id="F220821"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to sevoflurane, other halogenated inhalational anesthetics, or any component of the formulation; known or suspected genetic susceptibility to malignant hyperthermia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Occurrence of liver dysfunction, jaundice or unexplained fever, leukocytosis, or eosinophilia after previous halogenated anesthetic administration; when general anesthesia is contraindicated.</p></div>
<div class="block war drugH1Div" id="F220808"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Agitation/delirium: Monitor for emergence agitation or delirium (Stachnik 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Postoperative hepatitis (eg, jaundice associated with fever and/or eosinophilia) or hepatic dysfunction has been reported; prior exposure to halogenated hydrocarbon anesthetics may increase this risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: Use of inhaled anesthetics has been associated with rare cases of perioperative hyperkalemia in pediatric patients; concomitant use of succinylcholine was associated with most of the reported cases, but not all. Patients with latent and overt neuromuscular disease (eg, Duchenne muscular dystrophy) are the most vulnerable. Other abnormalities may include elevation in CPK and myoglobinuria. Monitor closely for arrhythmias. Aggressively identify and treat hyperkalemia and resistant arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Sevoflurane produces a dose-dependent reduction in blood pressure during maintenance of anesthesia and may occur more rapidly compared to other inhaled anesthetics.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intracranial pressure: May dilate the cerebral vasculature and may, in certain conditions, increase intracranial pressure (Stachnik 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignant hyperthermia: May trigger malignant hyperthermia; some reported cases have been fatal. Risk may be increased with concomitant administration of succinylcholine and volatile anesthetic agents and patients with genetic factors or family history of malignant hyperthermia, including ryanodine receptor or dihydropyridine receptor inherited variants. Signs of malignant hyperthermia may include arrhythmias, cyanosis, hemodynamic instability, hypercapnia, hyperthermia, hypovolemia, hypoxia, muscle rigidity, tachycardia, and tachypnea; coagulopathies, renal failure, and skin mottling may also occur. If malignant hyperthermia is suspected, discontinue triggering agents and institute appropriate therapy (eg, dantrolene) and other supportive measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: Cases of QT prolongation in association with torsade de pointes (some fatal) have been reported with sevoflurane use; use caution when administering to patients at risk of QT prolongation (eg, concurrent use of drugs that can prolong the QT interval such as class Ia and III antiarrhythmic drugs, elderly patients, congenital QT prolongation) (Han 2010; Kang 2006; Nakao 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory depression: May cause dose-dependent respiratory depression and blunted ventilatory response to hypoxia and hypercapnia (Golembiewski 2004); response may be augmented by other medications with respiratory depressant effect (eg, opioids). Hypoxic pulmonary vasoconstriction is blunted, which may lead to increased pulmonary shunt (Miller 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: In a scientific statement from the American Heart Association, sevoflurane has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; safety with severe impairment has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment (ie, creatinine &gt;1.5 mg/dL); safety with severe impairment has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients at risk for seizures; seizures have been reported in children and young adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Occupational caution: There is no specific work exposure limit established for sevoflurane. However, the National Institute for Occupational Safety and Health (NIOSH) has recommended an 8 hour time-weighted average limit of 2 ppm for halogenated anesthetic agents in general (0.5 ppm when coupled with exposure to N<sub>2</sub>O).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Desiccated absorbents: Reaction of sevoflurane with CO<sub>2</sub> absorbents that become desiccated within circle breathing equipment can lead to formation of formaldehyde (causing respiratory irritation) and carbon monoxide; maintain fresh absorbent as per manufacturer guidelines regardless of state of colorimetric indicator. An exothermic reaction occurs when sevoflurane is exposed to CO<sub>2</sub> absorbents; this reaction is increased when the CO<sub>2</sub> absorbent becomes desiccated. Rare cases of extreme heat, smoke, and/or fire within breathing circuit have been reported. This reaction also leads to formation of a fluorinated byproduct, compound A, which has been reported to cause mild and reversible renal injury in animal studies (Gentz 2001). The theoretical risk of compound A-induced nephrotoxicity in humans may be dose- and exposure time-dependent; minimize exposure risk by not exceeding 2 MAC hours and using fresh flow rates of 1 to &lt;2 L/minute (low fresh gas flow rates maximize rebreathing of the anesthetic). Steps to help reduce the risk of these events (eg, shutting off the anesthesia machine at the end of clinical use or after any case when a subsequent extended period of nonuse is expected, routine replacement of the CO<sub>2</sub> absorbents) should be incorporated into routine practice (Miller 2010).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878630"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Pediatric patients with trisomy 21 (Down syndrome) have been shown to be at an increased risk of developing bradycardia during anesthetic induction with sevoflurane. The mechanism for bradycardia is unknown. Some patients have failed to respond to traditional treatment options (eg, atropine). Dose reduction of sevoflurane and adequate oxygenation and ventilation were effective in most cases to reestablish baseline heart rates and hemodynamic stability (Bai 2010; Health Canada Safety Review 2018; Kraemer 2010; Roodman 2003; Walia 2016).</p></div>
<div class="block foc drugH1Div" id="F220816"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ultane:  (250 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic:  (100 mL [DSC], 250 mL)</p></div>
<div class="block geq drugH1Div" id="F220805"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block adm drugH1Div" id="F220818"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Via sevoflurane-specific calibrated vaporizers; use cautiously in low-flow or closed-circuit systems since sevoflurane is unstable and potentially toxic breakdown products have been liberated.</p></div>
<div class="block admp drugH1Div" id="F52613851"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Inhalation: Administer via sevoflurane-specific calibrated vaporizers; use cautiously in low-flow or closed-circuit systems since sevoflurane is unstable and potentially toxic breakdown products have been liberated.</p></div>
<div class="block use drugH1Div" id="F220817"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Anesthesia:</b> Induction and maintenance of general anesthesia in adults and pediatric patients for inpatient and outpatient surgery</p></div>
<div class="block mst drugH1Div" id="F220870"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ultane may be confused with Ultram</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F220860"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2A6 (minor), CYP2B6 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F220811"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bambuterol: May enhance the arrhythmogenic effect of Inhalational Anesthetics. Management: Some labels recommend specifically avoiding halothane; others recommend separating administration by at least 6 hours; other bambuterol labels do not mention this possible interaction. Monitor for increased sensitivity to arrhythmias if coadministered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers: Inhalational Anesthetics may enhance the hypotensive effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the hypertensive effect of Inhalational Anesthetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOPamine: Inhalational Anesthetics may enhance the arrhythmogenic effect of DOPamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). DroPERidol may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Consider dose reductions and monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ephedra: May enhance the arrhythmogenic effect of Inhalational Anesthetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Nasal): May enhance the arrhythmogenic effect of Inhalational Anesthetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): May enhance the arrhythmogenic effect of Inhalational Anesthetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Nasal): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Oral Inhalation): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Systemic).  Management: Administer epinephrine with added caution in patients receiving, or who have recently received, inhalational anesthetics. Use lower than normal doses of epinephrine and monitor for the development of cardiac arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenoterol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Fenoterol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Isoproterenol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaraminol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Metaraminol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the CNS depressant effect of Methadone. Methadone may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, sedation, and respiratory depression. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Sevoflurane. Specifically, the risk of hemodynamic instability may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Inhalational Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).  Management: When initiating a non-depolarizing neuromuscular blocking agent (NMBA) in a patient receiving an inhalational anesthetic, initial NMBA doses should be reduced 15% to 25% and doses of continuous infusions should be reduced 30% to 60%.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Norepinephrine: Inhalational Anesthetics may enhance the arrhythmogenic effect of Norepinephrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylephrine (Ophthalmic): May enhance the adverse/toxic effect of Inhalational Anesthetics. Specifically, the cardiovascular depressant effects of inhalational anesthetics may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the hypotensive effect of other QT-Prolonging Inhalational Anesthetics (Moderate Risk). QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the QTc-prolonging effect of other QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Monitor for hypotension and QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May enhance the adverse/toxic effect of Inhalational Anesthetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F14079770"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Sevoflurane crosses the placenta (Satoh 1995).</p>
<p style="text-indent:0em;margin-top:2em;">Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D- aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity, may affect brain development. Evaluate benefits and potential risks of fetal exposure to sevoflurane when duration of surgery is expected to be &gt;3 hours (Olutoye 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Use of sevoflurane in obstetric anesthesia has been described (ACOG 209 2019; Choi 2012; Devroe 2015; Gambling 1995; Karaman 2006). Maternal exposure should be minimized due to dose dependent uterine relaxation and fetal depression (ACOG 209 2019; Devroe 2015). Adverse events have not been observed following use as part of general anesthesia for elective cesarean delivery.</p>
<p style="text-indent:0em;margin-top:2em;">The ACOG recommends that pregnant women should not be denied medically necessary surgery, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 775 2019).</p></div>
<div class="block brc drugH1Div" id="F220823"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sevoflurane is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients can express and discard milk for the first 24 hours after administration to minimize infant exposure via breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The Academy of Breastfeeding Medicine recommends postponing elective surgery until milk supply and breastfeeding are established. Milk should be expressed ahead of surgery when possible. In general, when the child is healthy and full term, breastfeeding may resume, or milk may be expressed once the mother is awake and in recovery. For children who are at risk for apnea, hypotension, or hypotonia, milk may be saved for later use when the child is at lower risk (ABM [Reece-Stremtan 2017]).</p></div>
<div class="block mop drugH1Div" id="F220814"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP, temperature, heart rate and rhythm, respiration, oxygen saturation, end-tidal CO<sub>2</sub> and end-tidal sevoflurane concentrations should be monitored prior to and throughout anesthesia; temperature of CO<sub>2</sub> absorbent canister</p></div>
<div class="block pha drugH1Div" id="F864323"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhaled anesthetics alter activity of neuronal ion channels particularly the fast synaptic neurotransmitter receptors (nicotinic acetylcholine, GABA, and glutamate receptors). Limited effects on sympathetic stimulation including cardiovascular system. Sevoflurane does not cause respiratory irritation or circulatory stimulation. May depress myocardial contractility, decrease blood pressure through a decrease in systemic vascular resistance and decrease sympathetic nervous activity.</p></div>
<div class="block phk drugH1Div" id="F220820"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Sevoflurane has a low blood/gas partition coefficient and therefore is associated with a rapid onset of anesthesia and recovery </p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;">Onset of action: Time to induction: Within 2 to 3 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Emergence time: Depends on blood concentration when sevoflurane is discontinued. The rate of change of anesthetic concentration in the lung is rapid with sevoflurane because of its low blood gas solubility (0.63). The 90% decrement time (time required for anesthetic concentration in vessel-rich tissues to decrease by 90%) for sevoflurane is short when the duration of anesthesia is &lt;2 hours but increases dramatically as the duration of administration is lengthened (Bailey, 1997).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic (~5%) via CYP2E1 </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Exhaled gases</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F220824"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Eraldin | Sevocris | Sevocristalia | Sevoflurano baxter | Sevomax | Sevorane</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Sevofluran baxter | Sevofluran piramal | Sevorane</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane sandoz | Sevorane</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Sevorane</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane baxter | Sevorane</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Sevorane</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Anesevo | Sevocris | Sevoflurano | Sevoness | Sevorane | Voflur</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane baxter</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Sevorane</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Kai te li | Qi fu mei | Qifumei | Yi jun ning</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bloktec | Sevoflurano | Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Sevorane</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Sevorane</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Sevocris | Sevorane</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Seflur | Sevoflurano | Sevorane</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane baxter | Sevoflurane piramal | Sevorane</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane usp</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurano | Sevoflurano baxter | Sevoflurano piramal | Sevorane</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sevorane</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane baxter | Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane abbott | Sevorane</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Sevorane</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Sevorane</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Sevofluran baxter | Sevorane</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane baxter | Sevoflurane piramal | Sevorane</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Sevodex | Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane baxter | Sevorane</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Sevfurane | Sevitrue | Sevorane | Sevotroy | Sevura | Sojourn</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane baxter | Sevoflurane piramal | Sevorane</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Sevofrane abbott | Sevofrane aventis | Sevofrane maruishi | Sevoness</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Sevotroy | Ultane</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Baxter sevoflurane | Sevofran | Sevofrane | Sevoprane | Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane baxter | Sevoflurane piramal | Sevorane</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane piramal | Sevoran | Sevorane</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Sevorane</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Fhadotil | Floves | Savannlab | Sevam | Sevoflurano | Sevorane | Sovener | Svofast | Zurenpharm</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Ultane</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane baxter | Sevorane</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Servofluran Baxter | Sevorane</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Sevorane</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Inharane | Sevogesic | Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Baxter sevoflurane | Sevo | Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane baxter | Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Sojourn | Ultane</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurano | Sevoflurano ojourn | Sevorane</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Eraldin | Floves | Sevocris | Sevoflurano omicron | Sevoflurano prosalud | Sevoflurano quimfa | Sevoflurano usp interlabo | Sevorane</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Sojourn</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Sevo anesteran</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Sevofluran medisorb | Sevofluran vial | Sevoflurane vial | Sevorane | Sojurne</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Haluran | Sojourn</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Sevofluran baxter | Sevorane</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Sevofluran baxter | Sevofluran piramal | Sevorane</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Sevofluran baxter | Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Sefether | Sevoflurane baxter | Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane usp | Sevorane</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane baxter | Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Sevoflurane baxter | Sevofrane | Sojourn | Ultane</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Sevo anesteran | Sevorane</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Sevotroy</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Sevocris | Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sevorane | Sojourn</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Sojourn | Ultane</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Ultane</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Ultane</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 209: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913200">
<a name="30913200"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 775: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2019;133(4):e285-e286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/30913200/pubmed" id="30913200" target="_blank">30913200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21109130">
<a name="21109130"></a>Bai W, Voepel-Lewis T, Malviya S. Hemodynamic changes in children with Down syndrome during and following inhalation induction of anesthesia with sevoflurane. <i>J Clin Anesth</i>. 2010;22(8):592-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/21109130/pubmed" id="21109130" target="_blank">21109130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9296431">
<a name="9296431"></a>Bailey JM. Context-sensitive half-times and other decrement times of inhaled anesthetics. <i>Anesth Analg</i>. 1997;85(3):681-686.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/9296431/pubmed" id="9296431" target="_blank">9296431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19092335">
<a name="19092335"></a>Beck-Schimmer B, Breitenstein S, Urech S, et al, “A Randomized Controlled Trial on Pharmacological Preconditioning in Liver Surgery Using a Volatile Anesthetic,” <i>Ann Surg</i>, 2008, 248(6):909-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/19092335/pubmed" id="19092335" target="_blank">19092335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18627368">
<a name="18627368"></a>Bein B, Renner J, Caliebe D, et al, “The Effects of Interrupted or Continuous Administration of Sevoflurane on Preconditioning Before Cardio-Pulmonary Bypass in Coronary Artery Surgery: Comparison With Continuous Propofol,” <i> Anaesthesia</i>, 2008, 63(10):1046-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/18627368/pubmed" id="18627368" target="_blank">18627368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12761368">
<a name="12761368"></a>Campagna JA, Miller KW, and Forman SA, “Mechanisms of Action of Inhaled Anesthetics,” <i>N Engl J Med</i>, 2003, 348(21):2110-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/12761368/pubmed" id="12761368" target="_blank">12761368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22434266">
<a name="22434266"></a>Choi WJ, Kim SH, Koh WU, et al. Effect of pre-exposure to sevoflurane on the bispectral index in women undergoing Caesarean delivery under general anaesthesia. <i>Br J Anaesth</i>. 2012;108(6):990-997. doi: 10.1093/bja/aes036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/22434266/pubmed" id="22434266" target="_blank">22434266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15920178">
<a name="15920178"></a>De Hert SG, Turani F, Mathur S, et al, “Cardioprotection With Volatile Anesthetics: Mechanisms and Clinical Implications,” <i>Anesth Analg</i>, 2005, 100(6):1584-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/15920178/pubmed" id="15920178" target="_blank">15920178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25827280">
<a name="25827280"></a>Devroe S, Van de Velde M, Rex S. General anesthesia for caesarean section. <i>Curr Opin Anaesthesiol</i>. 2015;28(3):240-246. doi: 10.1097/ACO.0000000000000185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/25827280/pubmed" id="25827280" target="_blank">25827280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8443850">
<a name="8443850"></a>Doi M and Ikeda K, “Airway Irritation Produced by Volatile Anaesthetics During Brief Inhalation: Comparison of Halothane, Enflurane, Isoflurane and Sevoflurane,” <i>Can J Anaesth</i>, 1993, 40(2):122-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/8443850/pubmed" id="8443850" target="_blank">8443850</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Eger EI 2nd, “Characteristics of Anesthetic Agents Used for Induction and Maintenance of General Anesthesia,” <i>Am J Health Syst Pharm</i>, 2004, 61(Suppl 4):3-10.</div>
</li>
<li>
<div class="reference">
                  Food and Drug Administration. FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. <a href="https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm" target="_blank">https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm</a>. Published December 14, 2016. Accessed May 26, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1731542">
<a name="1731542"></a>Frink EJ Jr, Ghantous H, Malan TP, et al, “Plasma Inorganic Fluoride With Sevoflurane Anesthesia: Correlation With Indices of Hepatic and Renal Function,” <i>Anesth Analg</i>, 1992, 74(2):231-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/1731542/pubmed" id="1731542" target="_blank">1731542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7598289">
<a name="7598289"></a>Gambling DR, Sharma SK, White PF, Van Beveren T, Bala AS, Gouldson R. Use of sevoflurane during elective cesarean birth: a comparison with isoflurane and spinal anesthesia. <i>Anesth Analg</i>. 1995;81(1):90-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/7598289/pubmed" id="7598289" target="_blank">7598289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11772127">
<a name="11772127"></a>Gentz BA, Malan TP Jr. Renal toxicity with sevoflurane: a storm in a teacup? <i>Drugs</i>. 2001;61(15):2155-2162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/11772127/pubmed" id="11772127" target="_blank">11772127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15532144">
<a name="15532144"></a>Golembiewski J, “Considerations in Selecting an Inhaled Anesthetic Agent: Case Studies,” <i>Am J Health Syst Pharm</i>, 2004, 61 (Suppl 4):10-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/15532144/pubmed" id="15532144" target="_blank">15532144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20808206">
<a name="20808206"></a>Han DW, Park K, Jang SB, et al, “Modeling the Effect of Sevoflurane on Corrected QT Prolongation: A Pharmacodynamic Analysis,” <i>Anesthesiology</i>, 2010, 113(4):108-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/20808206/pubmed" id="20808206" target="_blank">20808206</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Healthy Canadians Recalls &amp; Alerts: Summary Safety Review - Sevoflurane - Re‑assessing the potential risk of slow heartbeat (bradycardia) in children with Down syndrome. Health Canada website. Available at: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00197 Published April 9, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2248821">
<a name="2248821"></a>Jones RM, “Desflurane and Sevoflurane: Inhalation Anaesthetics for This Decade?” <i>Br J Anaesth</i>, 1990, 65(4):527-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/2248821/pubmed" id="2248821" target="_blank">2248821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16645454">
<a name="16645454"></a>Kang J, Reynolds WP, Chen X, et al, “Mechanisms Underlying the QT interval-prolonging Effects of Sevoflurane and Its Interactions With Other QT-prolonging Drugs,” <i>Anesthesiology</i>, 2006, 104(5):1015-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/16645454/pubmed" id="16645454" target="_blank">16645454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16749414">
<a name="16749414"></a>Karaman S, Akercan F, Aldemir O, Terek MC, Yalaz M, Firat V. The maternal and neonatal effects of the volatile anaesthetic agents desflurane and sevoflurane in caesarean section: a prospective, randomized clinical study. <i>J Int Med Res</i>. 2006;34(2):183-192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/16749414/pubmed" id="16749414" target="_blank">16749414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9447851">
<a name="9447851"></a>Katoh T, Ijeda K. The effects of fentanyl on sevoflurane requirements for loss of consciousness and skin incision. <i>Anesthesiology</i>. 1998;88(1):18-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/9447851/pubmed" id="9447851" target="_blank">9447851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1389843">
<a name="1389843"></a>Katoh T, Suguro Y, Nakajima R, et al, “Blood Concentrations of Sevoflurane and Isoflurane on Recovery From Anaesthesia,” <i>Br J Anaesth</i>, 1992, 69(3):259-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/1389843/pubmed" id="1389843" target="_blank">1389843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20736433">
<a name="20736433"></a>Kraemer FW, Stricker PA, Gurnaney HG, et al. Bradycardia during induction of anesthesia with sevoflurane in children with Down syndrome. <i>Anesth Analg</i>. 2010;111(5):1259-1263.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/20736433/pubmed" id="20736433" target="_blank">20736433</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Miller RD. <i>Miller’s Anesthesia</i>. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20185656">
<a name="20185656"></a>Nakao S, Hatano K, Sumi C, et al, “Sevoflurane Causes Greater QTc Interval Prolongation in Elderly Patients Than in Younger Patients,” <i>Anesth Analg</i>, 2010, 110(3):775-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/20185656/pubmed" id="20185656" target="_blank">20185656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28888583">
<a name="28888583"></a>Olutoye OA, Baker BW, Belfort MA, Olutoye OO. Food and Drug Administration warning on anesthesia and brain development: implications for obstetric and fetal surgery. <i>Am J Obstet Gynecol</i>. 2018;218(1):98-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/28888583/pubmed" id="28888583" target="_blank">28888583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12846713">
<a name="12846713"></a>Roodman S, Bothwell M, Tobias JD. Bradycardia with sevoflurane induction in patients with trisomy 21. <i>Paediatr Anaesth</i>. 2003;13(6):538-540.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/12846713/pubmed" id="12846713" target="_blank">12846713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28921220">
<a name="28921220"></a>Satoh D, Iwatsuki N, Naito M, Sato M, Hashimoto Y. Comparison of the placental transfer of halothane, enflurane, sevoflurane, and isoflurane during cesarean section.<i> J Anesth</i>. 1995;9(3):220-223. doi: 10.1007/BF02479867.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/28921220/pubmed" id="28921220" target="_blank">28921220</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sevorane AF (sevoflurane) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1731547">
<a name="1731547"></a>Smith I, Ding Y, and White PF, “Comparison of Induction, Maintenance, and Recovery Characteristics of Sevoflurane-N20 and Propofol-Sevoflurane-N(2)O With Propofol-Isoflurane-N(2)O Anesthesia,” <i>Anesth Analg</i>, 1992, 74(2):253-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/1731547/pubmed" id="1731547" target="_blank">1731547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16554286">
<a name="16554286"></a>Stachnik J. Inhaled anesthetic agents. <i>Am J Health-Syst Pharm</i>. 2006;63(7):623-634.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/16554286/pubmed" id="16554286" target="_blank">16554286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3605675">
<a name="3605675"></a>Strum DP and Eger EI 2d, “Partition Coefficients for Sevoflurane in Human Blood, Saline, and Olive Oil,” <i>Anesth Analg</i>, 1987, 66(7):654-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/3605675/pubmed" id="3605675" target="_blank">3605675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ultane.1">
<a name="Ultane.1"></a>Ultane (sevoflurane) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26746603">
<a name="26746603"></a>Walia H, Ruda J, Tobias JD. Sevoflurane and bradycardia in infants with trisomy 21: A case report and review of the literature. <i>Int J Pediatr Otorhinolaryngol</i>. 2016;80:5-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/26746603/pubmed" id="26746603" target="_blank">26746603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17962069">
<a name="17962069"></a>Wang L, Traystman RJ, and Murphy SJ, “Inhalational Anesthetics as Preconditioning Agents in Ischemic Brain,” <i>Curr Opin Pharmacol</i>, 2008, 8(1):104-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/17962069/pubmed" id="17962069" target="_blank">17962069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1994760">
<a name="1994760"></a>Yasuda N, Lockhart SH, Eger EI 2nd, et al, “Comparison of Kinetics of Sevoflurane and Isoflurane in Humans,” <i>Anesth Analg</i>, 1991, 72(3):316-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevoflurane-drug-information/abstract-text/1994760/pubmed" id="1994760" target="_blank">1994760</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9887 Version 278.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
